Seattle Genetics, an emerging multi-product, global biotechnology company, develops and commercializes transformative cancer-targeting therapies. ADCETRIS® (brentuximab vedotin) utilizes the company's industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. We have a robust pipeline of novel targeted therapies to address significant unmet needs. We are headquartered in the U.S., with European and international operations in Switzerland. See www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
21823 30th Drive Southeast
Bothell, Washington 98021